ifosfamide has been researched along with Diffuse Lymphocytic Lymphoma, Poorly-Differentiated in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Pavlovsky, M | 1 |
| Cubero, D | 1 |
| Agreda-Vásquez, GP | 1 |
| Enrico, A | 1 |
| Mela-Osorio, MJ | 1 |
| San Sebastián, JA | 1 |
| Fogliatto, L | 1 |
| Ovilla, R | 1 |
| Avendano, O | 1 |
| Machnicki, G | 1 |
| Barreyro, P | 1 |
| Trufelli, D | 1 |
| Villanova, P | 1 |
| Alderuccio, JP | 1 |
| Saul, EE | 1 |
| Iyer, SG | 1 |
| Reis, IM | 1 |
| Alencar, AJ | 1 |
| Rosenblatt, JD | 2 |
| Lossos, IS | 2 |
| Hosein, PJ | 1 |
| Morgensztern, D | 1 |
| Coleman, F | 1 |
| Escalón, MP | 1 |
| Byrne, GE | 1 |
| Walker, GR | 1 |
| Stewart, DA | 1 |
| Duan, Q | 1 |
| Carlson, L | 1 |
| Russell, JA | 1 |
| Bahlis, NJ | 1 |
| Duggan, P | 1 |
| Hasegawa, W | 1 |
| Voralia, M | 1 |
| Cartier, JC | 1 |
| Truche, AS | 1 |
| Tonini, J | 1 |
| Zaoui, P | 1 |
| Carron, PL | 1 |
| Corazzelli, G | 1 |
| Russo, F | 1 |
| Capobianco, G | 1 |
| Marcacci, G | 1 |
| Della Cioppa, P | 1 |
| Pinto, A | 1 |
| Hertzberg, MS | 1 |
| Crombie, C | 1 |
| Benson, W | 1 |
| Taper, J | 1 |
| Gottlieb, D | 1 |
| Bradstock, KF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (R-MACLO/VAM) in Patients With Previously Untreated Mantle Cell Lymphoma[NCT00878254] | Phase 2 | 25 participants (Actual) | Interventional | 2009-03-25 | Active, not recruiting | ||
| Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (MACLO/IVAM) in Patients With Previously Untreated Mantle Cell Lymphoma[NCT00450801] | Phase 2 | 22 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Long-term Follow-up and/or Continued Thalidomide (THALOMID®) Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165[NCT02507336] | Phase 2 | 2 participants (Actual) | Interventional | 2015-11-24 | Completed | ||
| High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma[NCT00144092] | Phase 2 | 60 participants (Anticipated) | Interventional | 2001-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients experiencing adverse events during the course of protocol therapy. (NCT00450801)
Timeframe: Up to 5 years
| Intervention | participants (Number) |
|---|---|
| R-MACLO Cycles | 22 |
| R-IVAM Cycles | 22 |
| Thalidomide Therapy | 19 |
Percentage of participants achieving complete response (CR) to protocol therapy according to International Working Group Response Criteria for Non-Hodgkin's Lymphoma (NHL) using the CT imaging method. Patients were classified by best tumor response; CR was defined as normalization of the lactate dehydrogenase (LDH), complete disappearance of disease-related symptoms and lymph nodes, and clearance of lymphoma from involved organs; complete response unconfirmed (CRu) as a residual lymph node greater than 1.5 cm in greatest transverse diameter that had regressed by more than 75% or an indeterminate bone marrow examination; partial response (PR) as greater than 50% reduction in the involved lymph nodes, or disappearance of the involved lymph nodes but persistent bone marrow involvement; relapse/progression as new or increased lymph nodes, organomegaly, or reappearance of bone marrow involvement. (NCT00450801)
Timeframe: Up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| R-MACLO-IVAM-T | 100 |
Percentage of participants who are alive up to five years after receipt of protocol therapy. (NCT00450801)
Timeframe: Up to 5 years
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| 1-year rate overall survival Rate | 2-year overall survival Rate | 3-year overall survival rate | 4-year overall survival rate | 5-year overall survival rate | |
| R-MACLO-IVAM-T | 96 | 96 | 96 | 87 | 87 |
Percentage of participants achieving progression-free survival at 1, 3 and 5 years after the start of protocol therapy, based upon the International Working Group Response Criteria for Non-Hodgkin's Lymphoma (NHL). Progression is defined as a ≥ 50% increase from nadir in the product of the two largest perpendicular diameters (PPD-size) of any previously identified abnormal node, or appearance of any new lesion. (NCT00450801)
Timeframe: Up to 5 years
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 1 year progression-free survival | 3 year progression-free survival | 5-year progression-free survival | |
| R-MACLO-IVAM-T | 91 | 78 | 69 |
3 trials available for ifosfamide and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
4 other studies available for ifosfamide and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
| Article | Year |
|---|---|
Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Etoposid | 2022 |
Hemodialysis as a treatment of ifosfamide intoxication.
Topics: Humans; Ifosfamide; Lymphoma, Mantle-Cell; Male; Medication Errors; Middle Aged; Poisoning; Renal Di | 2013 |
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplati | 2006 |